drugset
drugset / Trial / NCT05077865

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865 ↗

Phase 1 Completed 32 enrolled TNF Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and pharmacokinetic properties. The study data will guide the establishment of an optimum therapeutic dose.

Timeline

Start
2021-04-26
Primary completion
2021-08-01
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MYMD-1 Unknown 150 mg Oral
Subject MYMD-1 Unknown 300 mg Oral
Subject MYMD-1 Unknown 450 mg Oral
Subject MYMD-1 Unknown 600 mg Oral

Indications

Hashimoto thyroiditis